GlassScriptPhysician profile
Howard S Young
NPI 1578563078
$2,578.52
in general payments reported to CMS, 2019-2025
24 companies · $484 in 2025
The $484 reported for 2025 was more than what a typical Critical Care Medicine (Internal Medicine) provider received nationally (typical 2025 total: $189).
See the full distribution for Critical Care Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,271 · 2021: $16.78 · 2022: $76.63 · 2023: $351 · 2024: $380 · 2025: $484.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,214.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,214.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $676.15 | 2019-2025 | Tezspire, Fasenra, Breztri |
| Glaxosmithkline, LLC. | $449.24 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $417.85 | 2019-2025 | |
| Insmed, INC. | $131.53 | 2019-2025 | Arikayce |
| Penumbra, INC. | $119.02 | 2019 | |
| Abbvie INC. | $93.63 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $82.79 | 2019-2024 | Dupixent |
| Genzyme Corporation | $68.23 | 2019-2025 | |
| Grifols USA, LLC | $64.35 | 2019-2025 | Xembify |
| Portola Pharmaceuticals, LLC | $62.57 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $59.46 | 2019-2023 | Uptravi, Opsumit |
| Electromed, INC. | $47.76 | 2019-2025 | Smartvest |
| Baxter Healthcare | $42.95 | 2023 | Hillrom - Life 2000 Ventilation System |
| Inspire Medical Systems, INC. | $36.76 | 2025 | Inspire |
| Mallinckrodt Enterprises LLC | $33.54 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Watermark Medical, INC. | $27.68 | 2024 | |
| Melinta Therapeutics, LLC | $26.90 | 2023 | Vabomere, Kimyrsa, Rezzayo |
| Mylan Specialty L.P. | $26.57 | 2019 | |
| Gilead Sciences, INC. | $21.51 | 2023 | |
| Genentech USA, INC. | $21.13 | 2019 | |
| Pfizer INC. | $20.67 | 2024 | |
| Jazz Pharmaceuticals INC. | $19.18 | 2019 | |
| Shire North American Group INC | $17.47 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $11.58 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Howard Young listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.